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Elevated bile acid levels increase hepatocellular car-
cinoma by unknown mechanisms. Here, we show
that mice with a severe defect in bile acid homeosta-
sis due to the loss of the nuclear receptors FXR and
SHP have enlarged livers, progenitor cell prolifera-
tion, and Yes-associated protein (YAP) activation
and develop spontaneous liver tumorigenesis. This
phenotype mirrors mice with loss of hippo kinases
or overexpression of their downstream target, YAP.
Bile acids act as upstream regulators of YAP via a
pathway dependent on the induction of the scaffold
protein IQGAP1. Patients with diverse biliary dys-
functions exhibit enhanced IQGAP1 and nuclear
YAP expression. Our findings reveal an unexpected
mechanism for bile acid regulation of liver growth
and tumorigenesis via the Hippo pathway.
INTRODUCTION
Hepatocellular carcinoma (HCC) is a leading cause of cancer
mortality, with poor prognosis and very few effective chemo-
therapy options. Several lines of evidence indicate that bile acids
(BAs) are promoters of hepatocarcinogenesis (Kitazawa et al.,
1990; Tsuda et al., 1988; Yang et al., 2007). BAs are produced
in the liver to facilitate the absorption of lipids and lipid-soluble
nutrients from the intestine (Hofmann, 1999; Russell, 2003).
BAs also function as signaling molecules and play important
roles in liver regeneration (Huang et al., 2006) as well as tumor
promotion (Kim et al., 2007). As detergents, they are potentially
cytotoxic, and their concentrations are tightly regulated at
several levels, including a negative feedback loop involving the
nuclear receptors farnesoid X receptor (FXR) and small hetero-
dimer partner (SHP) (Goodwin et al., 2000). Targeted deletion
of both of these receptors, but not either individually, leads to
marked elevation in hepatic BA levels and liver injury (Anakk1060 Cell Reports 5, 1060–1069, November 27, 2013 ª2013 The Autet al., 2011). The development of spontaneous liver tumors in
our Fxr/ Shp/ double-knockout (DKO) mouse model in
which mice have chronically elevated BA levels enabled us
to study the mechanisms that underlie BA-dependent tumor
promotion.
The mammalian Hippo pathway includes the serine/threonine
kinase Mst1/2, which phosphorylates and activates the down-
stream kinase Lats1/2, and their regulators, Mob1A/B and
Sav1. Lats1/2 phosphorylation of the transcriptional coactivators
Yes-associatedprotein (YAP) and transcriptional coactivatorwith
PDZ-binding motif (TAZ) causes them to be retained in the cyto-
plasm, inhibiting their ability to drive proliferation. Hippo signaling
is critical in regulating liver size (Cai et al., 2010; Camargo et al.,
2007; Dong et al., 2007; Lee et al., 2010; Song et al., 2010) and
intestinal regeneration (Cai et al., 2010; Karpowicz et al., 2010;
Staley and Irvine, 2010). Notably, downregulation of Mst1/2 or
overexpression of YAP in mouse liver results in hepatocellular
carcinoma (HCC) (Cai et al., 2010; Dong et al., 2007). While the
core components of this pathway are well defined, its upstream
regulators are still being sought after. Cell-cell contact sup-
presses the pathway via factors such as atypical cadherins
(Hamaratoglu et al., 2006), a-catenin (Schlegelmilch et al.,
2011), and the apical adaptor proteins Kibra-Expanded and
Merlin (Cai et al., 2010; Genevet et al., 2010; Grusche et al.,
2010; Hamaratoglu et al., 2006). Decreased cell density or
increased extracellular matrix stiffness was shown to increase
nuclear localization of YAP and TAZ (Dupont et al., 2011; Schle-
gelmilch et al., 2011). Recently, G protein coupled receptors
have been suggested as upstream regulators of the Hippo path-
way in mammalian cells (Mo et al., 2012; Yu et al., 2012).
The increased liver size, hepatocyte proliferation, and subse-
quent development of spontaneous HCC in DKO mice strongly
resembled the phenotype of mammalian Hippo pathway
Mst1/2 liver-specific knockouts. (Anakk et al., 2011; Lee et al.,
2010; Lu et al., 2010; Song et al., 2010). Consistent with this
overlap, we found that elevated BA levels are sufficient to
activate YAP in both livers and isolated hepatocytes, and we
identified induction of the scaffolding protein IQGAP1 as a key
intermediate in this process.hors
Figure 1. Fxr/Shp/ Mice Develop Spontaneous Hepatocellular Carcinoma and Phenocopy Mst1//Mst2/ Mice
(A) Gross liver examination shows the presence of multiple tumor nodes with 100% penetrance compared to tumor-free WT mice (n = 20).
(B) Progressive tumor growth is evident from increasing liver to body weight ratio of DKO mice with age.
(C–E) Hepatic oval cell marker, OC21D11 (red), shows increased staining in 8- to 10-week-old DKO (D) compared toWT (C) mice and its quantification is shown in
(E). DAPI (blue) stains the nuclei (n = 4–6).
(F–H) Hematoxylin and eosin (H&E) staining of a year-old normal liver WT (F) and a DKO liver (G and H). DKO mice develop adenomas, whose growth rate
exceeds the adjacent host liver (G), and HCC, with marked nuclear atypia and mitotic activity (H); the inset shows cholangiofibrosis. Arrowheads show fat
accumulation, arrows point to focal inflammation, and the dotted line demarcates the adenoma boundary from the injured liver tissue. Magnification is 1203, and
insets are 2503.
*p < 0.05, **p < 0.001 compared to WT.RESULTS
Fxr/Shp/Mice PhenocopyMst1/Mst2 Liver-Specific
Knockouts
Combined loss of FXR andSHP results in early-onset cholestasis
(Anakk et al., 2011). In accord with the tumor-promoting effects
of BAs, we observed spontaneous hepatic tumorigenesis in
year-old DKOmice, which are maintained on the tumor-resistant
C57/B6 mouse background (Figure 1A). DKO mice develop
tumor nodules as early as 9 months, and by 12 months we can
see well-developed adenomas that spread through the entire
liver between 15 and 17 months of age (Figure 1B). Additionally,
OC2-1D11, a marker for a hepatic progenitor/oval cell popula-Cell Retion, is dramatically increased in DKO mice compared to wild-
type (WT) mice as early as 8–10 weeks of age (Figures 1C–1E).
Histological analysis of DKO tumors revealed heterogeneous
hepatocyte populations with injury, cholangiofibrosis, and multi-
ple adenomas that can progress to hepatocellular carcinoma
(Figures 1F–1H) consistent with what is observed in HCC
patients (Llovet et al., 2003).
These results revealed a striking overlap of DKO and Mst1/2
knockout phenotypes, including an increase in the hepatic pro-
genitor/oval cell population and aggressive liver tumors (Lu
et al., 2010; Song et al., 2010). This overlap was reinforced by
the observation that Mst1/2 knockout mice also accumulated
hepatic BAs (Figures S1A–S1C).ports 5, 1060–1069, November 27, 2013 ª2013 The Authors 1061
Figure 2. BA Overload Is Sufficient to
Induce YAP Activation
(A) Gene expression analysis in DKO mice in-
dicates induction of YAP targets.
(B) Immunoblot confirms reduced levels of inactive
phospho YAP and activation of its targets in 5- to
8-week-old DKO animals compared to WT.
(C) WT primary hepatocytes upon treatment with
DKO serum display YAP activation, which can be
mimicked with the bile acid chenodeoxycholic
acid (CDCA).
(D) CDCA induces YAP target CTGF.
(E and F) WT mice fed a 1% CA diet (E) or 0.1%
DDC diet (F) for 2 weeks display YAP activation
compared to chow-fed animals.
Densitometry was performed on immunoblots for
n = 3–5 animals per group, and fold differences in
comparison to control WT are written in paren-
theses.YAP Is Activated in the Livers of DKO Mice
Consistent with the above observation, microarray analysis re-
vealed a significant upregulation of YAP targets, including con-
nective tissue growth factor (CTGF), Cyclin D1, and Osteopontin
(SPP1), with no change in YapRNA in DKO livers (Figure 2A), and
these responses were validated at the protein level (Figure 2B).
Unlike in DKO mice, YAP activation was not observed in indi-
vidual Fxr/ and Shp/ knockouts (Table S1; Figures S2A–
S2D). Moreover, a role for FXR in YAP activation is ruled out by
the observation that treating WT mice with the synthetic FXR
agonist GW4064 resulted in the expected induction of Shp and
bile salt export pump (Bsep) expression (data not shown) but
did not change inactive phospho-YAP levels (Figures S2C–
S2D). These results clearly indicate that activation of YAP in
the DKO livers is FXR and SHP independent.
Next, we hypothesized that the YAP activation is secondary to
the sharply elevated BA levels observed in the DKO mice (Fig-
ure S3) rather than a cell-autonomous effect of the loss of FXR
and SHP. To test this hypothesis, we cultured WT primary hepa-
tocytes in media containing serum from either WT or DKO mice.
We observed a decrease in inactive phospho-YAP only in
response to DKO serum treatment, indicating that an extrinsic
circulating factor was responsible for the activation of YAP (Fig-
ure 2C). Further, treatment of WT primary hepatocyte with the
DKO serum preincubated with the BA binding resin cholestyr-
amine reduced DKO BA levels by 50% and increased inactive
phospho-YAP levels (Figures S4A and S4B). These experiments
indicated BAs as putative upstream regulators of YAP activation.
A High Concentration of BAs Activates YAP Signaling
To directly examine whether elevated BAs function as the
extrinsic signal that causes YAP activation, WT primary hepato-
cytes and the liver cell line AML12 were treated with varying con-1062 Cell Reports 5, 1060–1069, November 27, 2013 ª2013 The Authorscentrations of the relatively hydrophobic
BA chenodeoxycholic acid (CDCA), which
does not require transporters to enter the
cell. YAP was activated and its target
CTGF was induced in a dose-dependentmanner by CDCA at 150 mM (Figure 2D; Figures S4C and S4D).
To determine whether this YAP activation is a consequence of
possible CDCA toxicity, we performed TUNEL staining. We
found that 150 mMCDCA overnight treatment had only a modest
impact on cell death compared to vehicle in WT primary hepato-
cytes (Figures 3A–3E).
We then utilized two different dietary models to increase BA
levels in vivo to confirm the ability of BAs to dysregulate Hippo
signaling in mice. Naive WT mice were fed diets supplemented
with either 1% cholic acid (CA), a primary BA that is relatively
well tolerated by mice, or 0.1% 3,5-diethoxycarbonyl-1,4-dihy-
droxychollidine (DDC), an inhibitor of heme biosynthesis that in-
duces both BA overload and oval cell proliferation (Lee et al.,
2010; Wang et al., 2003). Elevated BA levels in both of these
models were sufficient to robustly decrease inactive phospho-
YAP (Figures 2E and 2F).
Overall, these results indicate that a normal physiological
concentrationofBAsdoesnot activateYAP; rather, this activation
is dependent on pathological BA overload achieved in the cell-
based models and in DKO mice or in cholestatic models.
As an initial approach to identify themechanism underlying the
observed YAP activation, we examined the canonical hippo
pathway proteins. Key hippo kinases Mst1, Lats1, and phos-
pho-Lats1/2 were all downregulated in DKO mice compared to
WT animals (Figure 3F). Despite the decrease in Mst1 protein
levels, we failed to observe any alteration in active phospho-
Mst1/2 levels (Figure 3F) and the functional adaptor proteins
salvador (sav1) and Mob1 (data not shown). Consistent with
this result, Mst1 and Lats 1 levels were reduced upon CA feeding
in WT animals (Figure 3G). However, despite activating YAP like
in the CA-fed WT or the DKO mice, DDC-diet-treated mice did
not show any changes in the upstream hippo pathway kinases
(Figure 3H). Overall, these results indicate that modulation of
Figure 3. BA Overload Does Not Cause Overt Cell Death but Alters Canonical Hippo Signaling
(A–D) Primary hepatocytes were cultured and treated with DMSO (A) and varying doses of CDCA (B–D) overnight.
(E) Cells were fixed and TUNEL-positive green-stained nuclei (marked with white arrows) were counted in at least ten different fields for each of the treatment
groups to quantify cell death. We performed this experiment in triplicate. **p < 0.001 when compared to WT, CDCA 75 mM; #p < 0.01 when compared to CDCA
150 mM. Magnification is 1203.
(F–H) Immunoblots for hippo pathway kinases were performed in DKO (F) and WT animals treated with either 1% CA (G) or 0.1% DDC (H) for 2 weeks. Hippo
kinases were altered only in DKO and in CA-fed mice with no changes in DDC-fedWT animals. However, YAP targets CTGF and Cyclin D1 were induced upon CA
and DDC treatment, clearly indicating YAP activation in these cholestatic mouse models. Densitometry was performed on immunoblots for n = 3–4 animals per
group. Fold differences in comparison to control WT are in parentheses.the canonical Hippo pathway may be involved in BA-mediated
YAP activation but is not essential.
Alteration in Cell Adhesion Is Central to BA-Mediated
YAP Activation
Apart from FXR and SHP, BAs can signal through multiple
pathways, suchasbyGproteincoupled receptorTGR5,orbyacti-
vating the kinase cascade, including c-Jun N-terminal kinase
(JNK) (Yu et al., 2005), extracellular signal-regulated kinase
(ERK) (Dent et al., 2005), or p38 MAPK (Kurz et al., 2001), and via
their detergent action. To systematically address the potential
mechanisms by which high levels of BA result in YAP activation,
we screened hepatic lysates from DKO and WT mice using a
reverse-phase protein array with antibodies to 187 signaling mol-
ecules, including kinases, adaptors, extracellular matrix proteins,
and cyclins (Cheng et al., 2005). None of the knownBA kinase tar-
gets, includingp38MAPK,ERK,orJNKpathways,wereactivated;Cell Reinstead, total ERK and epidermal growth factor receptor were
downregulated in DKO mouse livers compared to WT. Among
the 29 proteins with statistically significant differences in DKO
compared to WT livers (Figure S5A), a decrease in the cell adhe-
sion protein E-cadherin (Figure S5B) was consistent with a recent
report that decreased E-cadherin levels increase YAP activation
(Kim et al., 2011). In accord with this, CDCA treatment decreased
E-cadherin protein levels inWTprimary hepatocytes (Figure S5C).
IQGAP1 Is Induced during Biliary Overload and
Promotes Hepatic Tumorigenesis
IQGAP1 (IQmotif containingGTPase activating protein 1) is a key
scaffolding protein that interacts with E-cadherin (Kim et al.,
2011) and PP2A (Brown and Sacks, 2006). IQGAP1 modulates
cell adhesion by regulating E-cadherin and b-catenin (Roy
et al., 2005), and IQGAP1 overexpression reduces cellular
adhesion by dissociating a-catenin from the cadherin-cateninports 5, 1060–1069, November 27, 2013 ª2013 The Authors 1063
Figure 4. Increased IQGAP1 Expression Correlates Strongly with YAP Activation
(A–C) Iqgap1 is robustly induced in DKO (A), WT (B), and in Iqgap2/ animals treated with a 1% CA diet (C) compared to their respective controls.
(D–F) The 1% CA treatment leads to elevated liver enzymes in the serum of Iqgap2/ mice.
(G) Immunoblot shows YAP activation in naive Iqgap2/ mice.
(H) Immunohistochemistry reveals abundant YAP expression with increased nuclear YAP in Iqgap2/ compared to WT mouse livers after 1%CA diet (insets).
Magnification is 1203. *p < 0.05 compared to WT mice on normal chow.complex (Kuroda et al., 1998). IQGAP1 is typically expressed at
negligible levels in normal liver, but its potential contribution of to
hepatocarcinogenesis is evident from the observations that its
expression is elevated in HCC (White et al., 2010) and that loss
of Iqgap1 on an Iqgap2/mouse background blocked develop-
ment of hepatic tumorigenesis (Schmidt et al., 2008). DKO mice
displayed robust induction of IQGAP1 protein compared to WT
(Figure 4A), which would decrease cellular adhesion and subse-
quently trigger YAP activation in the livers of DKOmice. To test if
elevated BA levels induce IQGAP1, we fed WT mice a diet
enriched in CA, which, remarkably, led to a strong induction of
hepatic IQGAP1 in WT mice (Figure 4B). These data link BA-
mediated IQGAP1 induction to the development of spontaneous
liver tumorigenesis.
To investigate the connection between IQGAP1 induction and
YAP activation, we examined phospho-YAP levels in Iqgap1/
and Iqgap2/ mice and found strong YAP activation in
Iqgap2/ mice (Figure 4C), which have elevated levels of
IQGAP1. Further, this activation was blunted in Iqgap1/ livers.
Next, we tested whether IQGAP1 induction was required for
BA-mediated YAP activation by challenging Iqgap1/ and
Iqgap2/ mice with BA overload by feeding them a 1% CA
diet. CA diet led to the expected increase of liver enzymes in1064 Cell Reports 5, 1060–1069, November 27, 2013 ª2013 The Autserum (Figures 4D–4F) and IQGAP1 levels (Figure 4G), along
with increased nuclear YAP staining in Iqgap2/ mice when
compared to WT mice (Figure 4H). Moreover, hepatocyte prolif-
eration uponCA diet was significantly reduced in Iqgap1/mice
compared to WT and Iqgap2/ mice (Figures 5A–5G). These
results indicate that IQGAP1 protein induction is crucial to BA-
mediated YAP activation and hepatocyte proliferation.
IQGAP1 Overexpression Is Sufficient to Induce YAP
Activation
Weusedadenoviral Iqgap1overexpression todeterminewhether
increased IQGAP1 was sufficient to induce YAP activation.
We verified strong hepatic expression of IQGAP1and a robust
increase in YAP expression in hepatocytes, which was com-
pletely absent in the control Adeno GFP (Figures 6A and 6H).
These data clearly show that overexpression of Iqgap1 can drive
YAP expression and activation in mouse livers. Increased
IQGAP1 expression resulted in a modest elevation of serum
alanine amino transferase (ALT), but not aspartate amino
transferase (AST) (Figures 6C and 6D), and increased liver size
(Figures 6Eand6F)with nochange in serumBA levels (Figure 6G).
In addition, nuclear Ki-67 staining increased upon IQGAP1
overexpression (Figure 6H inset). Overall, we conclude thathors
Figure 5. Iqgap1 Is Crucial for BA-Mediated Hepatocyte Proliferation
(A–F) WT (A and B), Iqgap1/ (C and D), and Iqgap2/ (E and F) mice were fed a 1% CA diet for 2 weeks.
(G) Ki-67 staining was performed in these samples to assess cellular proliferation. n = 3–4 mice per group were stained with Ki-67, and the positively stained
brown nuclei were quantified.
*p < 0.001 compared to WT a and Iqgap2/ b. Magnification used is 1203.chronically elevated BA levels induce IQGAP1 and that the
elevated IQGAP1 is required for full YAP activation.
Cholestatic Individuals and Human Liver Tumors Exhibit
High Expression of YAP and IQGAP1
We then examined whether BA-mediated activation of Hippo
signaling is conserved in human livers. We screened 26 patients
ranging in age from 2 weeks to 16 years with diverse biliary
diseases resulting in cholestasis and liver cancer. We analyzed
both YAP and IQGAP1 expression levels in these liver biopsies
and found that cholestatic livers displayed robust YAP staining in
hepatocytes compared to normal tissue or diseased livers without
bile retention (Figures 7A–7D). YAPwas also detected in a few he-
patic adenomas with no detectable hepatic IQGAP1 expression,
whereas YAP and IQGAP1 were robustly expressed in hepatocel-
lular carcinoma (Figure 7E). Further, bile ducts expressed YAP and
IQGAP1 in normal livers and in proliferative ducts and ductules,
with overall increased expression in the cholestatic situation. It is
important to note that bile ducts, which are exposed to a high con-
centration of BAs, maintain IQGAP1 and YAP expression, indi-
cating a functional interplay of BAs, IQGAP1, and YAP.
DISCUSSION
HCC is one of the most deadly human cancers (Han, 2012), with
poor therapeuticoptions. It is commonlyassociatedwithhepatitis
B virus (HBV) or hepatitis C virus (HCV) infection, but the
underlying molecular mechanism is poorly understood. A major
barrier to understanding HCC is its inherent heterogeneity, with
distinctsubtypes linked todifferentpotential oncogenicpathways
(Lee and Thorgeirsson, 2005; Nault and Zucman-Rossi, 2011).
BAs are intrinsic signaling molecules in hepatocytes and are
elevated in HCC (Tsuboyama et al., 2010) and increase HBVCell Re(Kim et al., 2010) andHCV (Chang andGeorge, 2007) expression.
BAs are known to promote hepatic tumorigenesis (Shiota et al.,
1999; Yang et al., 2007), but how this occurs is not clear. By utiliz-
ing Fxr/Shp/ mice, which have chronically elevated BA
levels,we examined howBAs could function as tumor promoters.
Our results identify BAs as upstream regulators of the Hippo
pathway. This pathway and its target, YAP, have been recently
identified as crucial drivers for liver growth and tumorigenesis
(Zhou et al., 2009; Cai et al., 2010; Lu et al., 2010; Song et al.,
2010). Thus, we propose that BAs function as tumor promoters
by driving YAP activation. The ability of BAs to activate YAP is
concentration dependent. Normal physiological or modestly
elevated concentrations of BA do not result in YAP activation,
but chronically elevated pathological concentrations of more
than 100 mM, which are commonly observed in cholestatic
patients (Murphy et al., 1972; Neale et al., 1971), activate YAP
and could promote tumorigenesis. Recently, YAP was shown
to be important for bile duct and hepatocyte proliferation after
cholestatic injury, which is in accord with our data and sup-
ports the interplay between BAs and YAP (Bai et al., 2012).
Furthermore, the downregulation of both FXR and SHP in all
the different stages of HCC (Wolfe et al., 2011; Yang et al.,
2007) provides additional clinical relevance for our findings.
Liver tumors occur in single Fxr/ and Shp/ mice at
15 months of age (Yang et al., 2007), and the underlying mecha-
nism for tumor formation is either via elevated proinflammatory
cascade (Wang et al., 2008) or by increased cellular proliferation
(Zhang et al., 2008). BA concentrations do not reach more than
100 mM even at 6–9 months of age in Fxr/ or Shp/ (Liu
et al., 2012) mice, and consistent with that we do not observe
YAP activation in these knockouts.
The strong decrease in Lats1 and Mst1/2 levels and a modest
decrease in terminal phospho-lats1/2 with unchanged levels ofports 5, 1060–1069, November 27, 2013 ª2013 The Authors 1065
Figure 6. IQGAP1 overexpression Is Sufficient to Increase YAP Levels and to Increase Hepatocyte Proliferation
(A) Hepatic Iqgap1 overexpression results in YAP activation.
(B) This is quantitated using immunoblots.
(C–G) Iqgap1 overexpression for a period of 2 weeks results in slightly elevated serum ALT, but not AST, levels (C and D) and increased liver size (E and F) with no
change in serum bile acid concentration (G).
Robust YAP expression is observed in all hepatocytes after Iqgap1 overexpression, which correlates well with the increased proliferation observed with
Ki-67 staining (inset). Densitometry on immunoblots for n = 3–5 animals per group. Fold differences in comparison to controlWT are in parentheses.Magnification
is 1203, and insets are 2503. *p < 0.05 compared to WT.phospho-Mst1/2 in DKO mice show that the canonical Hippo
pathway is affected in theDKOmice. However, similar responses
were not observed in the DDC-fedmice andmay not be essential
for YAP activation in response to elevated BA. Noncanonical
Hippo/Mst-independent activation of YAP was recently
described in both Drosophila and mammalian cells (Kim et al.,
2013; Yin et al., 2013; Yu et al., 2013). In addition to the potential
input of the Hippo pathway, we found that elevated BA levels
could activate YAP by disrupting signaling at the plasma mem-
brane. Thus, the decrease in E-cadherin levels in DKO mice
concurs with the recent study linking E-cadherin activity to
YAP activation (Kim et al., 2011). The signaling scaffold pro-
tein IQGAP1, which interacts with E-cadherin to decrease
its expression, is dramatically upregulated in DKO livers. Inter-1066 Cell Reports 5, 1060–1069, November 27, 2013 ª2013 The Autestingly, IQGAP1 also interacts with the protein phosphatase
PP2A,which stabilizes the interaction of IQGAP1with E-cadherin
(Takahashi and Suzuki, 2006). We have recently found that
PP2A levels are also increased in the DKO livers (Jiang et al.,
2013). Increased PP2A activity could also contribute to YAP acti-
vation via dephosphorylation at S127 (Schlegelmilch et al., 2011).
In gain-of-function studies, we demonstrated that overex-
pression of IQGAP1 in WT liver is sufficient to activate YAP
and induce an acute proliferative response (Figure 6). We
conclude that the induction of IQGAP1 by BAs is necessary for
full YAP activation and can drive YAP expression in the absence
of the BA stimulus.
Liver cancer is strongly associated with human cholestatic
syndromes (Davit-Spraul et al., 2010; Silveira et al., 2008;hors
Figure 7. Human Biliary Disorders Exhibit Strong YAP and IQGAP1 Expression
(A) Normal liver: bile duct epithelium has uniform cytoplasmic expression of both YAP and IQGAP1 proteins. Arterial smooth muscle is also positive. IQGAP1 is
also expressed in sinusoidal Kupffer cells.
(B) A 2 year old with congenital hepatic fibrosis: all ducts express IQGAP1 and YAP in cytoplasm and YAP in some nuclei.
(C) Extrahepatic biliary atresia in a 2 week old. In addition to ductular expression of both proteins in the cytoplasm, many ductal and ductular and some
hepatocyte nuclei are positive for YAP.
(D) PFIC3 (progressive familial intrahepatic cholestasis 3). The expression pattern is identical to that of extra hepatic biliary atresia. Original magnification is 1203
with purple staining for YAP (top) and red staining for IQGAP1 (bottom).
(E) Human adenoma and hepatocellular carcinoma samples stained with YAP and IQGAP1.
(F) Model illustrating how elevated BAs cause YAP activation.Strautnieks et al., 2008), with 15% incidence of HCC or cholan-
giocarcinoma in progressive familial intrahepatic cholestasis 2
(PFIC2) patients as a consequence of genetic loss in Bsep.
Increased YAP levels are observed specifically in liver tumors
and strongly correlate with poor survival (Xu et al., 2009). Thus,
maintaining appropriate BA levels early on in cholestasis will
not only improve liver pathology but may also prevent subse-
quent YAP activation and hepatocarcinogenesis.
EXPERIMENTAL PROCEDURES
Animals
WTC57BL/6mice,Fxr/,Shp/, andDKOcongenic, age-matchedmalemice
were used throughout this study. WT control mice were purchased fromHarlan
Sprague Dawley. Mice were sacrificed at 5 weeks, 8–10 weeks, or 12 and
17 months after birth. Control, Iqgap1/, and Iqgap2/ age-matched male
mice were also used in this study. To study BA overload, mice were either fed
normal, 1% CA or 0.1% DDC supplemented chow for a period of 2 weeks. At
the end of the experiment, bloodwas collected and liver tissue was flash frozen
in liquid nitrogen. Mice were housed on a standard 12 hr light/dark cycle and
were fednormal chowandwater ad libitum.All animal experimentswere carried
out asoutlined in theGuide for theCare andUseof LaboratoryAnimalspreparedCell Reby theNational AcademyofSciences andpublishedby theNational Institutesof
Health (National Institutes of Health publication 86-23, revised 1985).
Histology
Liver samples were fixed in 10% formalin or snap frozen in optimal cutting
temperature compound. The formalin-fixed sections were used for hema-
toxylin and eosin staining. Frozen liver sections were used to detect oval
cell-specific marker OC2-1D11 by immunofluorescence as described previ-
ously (Dorrell et al., 2008). For quantification of oval cells, three mice per group
were used. Random multiple pictures (10–15 per slide) were taken using an
Axioplan fluorescent microscope and quantitated using Metamorph software.
Human liver biopsy specimens were stained using YAP antibody (Epitomics)
at 1:400 dilution and Iqgap1 antibody (Epitomics) at 1:50 dilution followed by
a substrate-chromogen (AEC).
Tissue BA Analysis
A total of 100 mg of frozen liver tissue was weighed and shipped to
Metabolon to determine bile acid levels using liquid chromatography mass
spectrometry.
Gene Expression Analysis
Total RNA from liver was prepared according to manufacturer’s protocol
(TRIzol; Invitrogen). The RNA obtained was further purified using Qiagenports 5, 1060–1069, November 27, 2013 ª2013 The Authors 1067
columns for microarray analysis. Microarray analysis was performed on the
Illumina mouseRefseq-8 Expression platform as previously described (Anakk
et al., 2011).
Western Blot Analysis
Protein was extracted from 100mg of fresh liver with a Dounce homogenizer in
10 mM HEPES (pH 7.5), 0.32 M sucrose, 1% SDS, 5 mM MG132, and 5 mM
EDTA with protease and phosphatase inhibitors. For western blot, 30–50 mg
total protein was used. The membrane was incubated with a dilution of
1:5,000 p-YAP (Epitomics) or 1:1,000 of CTGF (Abcam), Iqgap1 (Epitomics),
and total YAP, JNK, p-JNK, Erk, p-Erk, Akt, p-Akt, E-cadherin, b-actin, or
1:300 Cyclin D1, Mst1, Mst2, p-LATS1/2, LATS1, and p-Mst1/2 (Cell Signaling
Technology) and developed.
Primary Hepatocyte Culture
Mouse hepatocytes were prepared using a modified two-step perfusion
technique as previously described (Seglen, 1976). Primary hepatocytes were
seeded at 100% confluence on to six-well plates and treated with DMSO,
CDCA (75 mM, 150 mM), and 20% WT or DKO serum for 16–18 hr.
TUNEL Assay
Mouse primary hepatocytes were prepared and treated with varying concen-
tration of CDCA as mentioned above. TUNEL (Roche) was performed accord-
ing to the manufacturer’s instructions.
Adenoviral Infection
Full-length Iqgap1 cDNA was obtained from Origene Technologies and was
cloned into pAdenoX expression system from Clone Tech. Positive clones
were identified by sequencing. Adenovirus expressing Iqgap1 or GFP was
amplified and purified to perform tail vein injection in mice.
Data Analysis
Data were analyzed using a one-way ANOVA with the post hoc Bonferroni test
for comparison of multiple groups or an unpaired Student’s t test for compar-
ison between two groups (*p < 0.05 and **p < 0.001 when compared to their
respective age-matched WT controls).
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